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Abstract
Background: To explore the feasibility of constructing engineered myocardial tissues (EMTs) in vivo, using
polylactic acid -co-glycolic acid (PLGA) for scaffold and cardiomyocyte-like cells derived from bone marrow
mesenchymal stem cells (BMMSCs) for seeded cells.
Methods: BMMSCs were isolated from femur and tibia of Sprague-Dawley (SD) rats by density-gradient
centrifugation. The third passage cells were treated with 10 μmol/L 5-azacytidine (5-aza) and 0.1 μmol/L
angiotensin II (Ang II) for 24 h, followed by culturing in complete medium for 3 weeks to differentiated into
cardiomyocyte-like cells. The cardiomyocyte-like cells were seeded into PLGA scaffolds to form the grafts. The grafts
were cultured in the incubator for three days and then implanted into the peritoneal cavity of SD rats. Four weeks
later, routine hematoxylin-eosin (HE) staining, immunohistochemical staining for myocardium-specific cardiac
troponin I (cTnI), scanning electron microscopy and transmission electron microscopy were used to analyze the
morphology and microconstruction of the EMTs in host rats.
Results: HE staining showed that the cardiomyocyte-like cells distributed equally in the PLGA scaffold, and the
nuclei arranged in the spindle shape. Immunohistochemical staining revealed that majority of engrafted cells in the
PLGA -Cardiomyocyte-like cells group were positive for cTnI. Scanning electron microscopy showed that the
inoculated cells well attached to PLGA and grew in 3 dimensions in construct. Transmission electron microscopy
showed that the EMTs contained well arranged myofilaments paralleled to the longitudinal cell axis, the cells were
rich in endoplasmic reticulum and mitochondria, while desmosomes, gap junction and Z line-like substances were
also can be observed as well within the engrafted cells.
Conclusion: We have developed an in vivo method to construct engineered myocardial tissue. The in vivo
microenvironment helped engrafted cells/tissue survive and share similarities with the native heart tissue.
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Background
Ischemic heart disease and dilated cardiomyopathy are
the major causes of morbidity and mortality worldwide.
The limited capability of the surviving cardiomyocytes
to proliferate render the damaged heart susceptible to
unfavorable remodeling processes and morbid sequelae
such as heart failure [1]. Established pharmacologic
treatment can decelerate but not stop the progression of
heart failure once a significant part of the myocardium
tissue is damaged. Currently heart transplantation is the
only viable treatment option for end-stage heart failure
patients. Given the persistent shortage of donor heart
organs’ donation, stem cell therapy has emerged as a
promising cell resources for healing final stage heart dis-
ease because it provides a virtually ideal source of cardi-
omyocytes, endothelial cells, and other differentiated cell
types.
The efficacy of stem cell transplantation has been
demonstrated by many animal and clinical studies. Dif-
ferent cell types have been proposed for cardiac regen-
eration, including embryonic stem cells, skeletal
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mononuclear cells [2-4]. In these cell types, bone mar-
row mesenchymal stem cells (BMMSCs) have gained
attention as an easily accessible, homogeneous cell
population for cardiac repair. Tissue engineering with
stem cell, aiming at restoring, maintaining or enhancing
tissue and organ function, provides a potential therapeu-
tic alternative to whole organ transplantation and offers
the possibility of creating functional tissue equivalents
for scientific studies and tissue repair [5].
Myocardial tissue engineering is an emerging technique
that combines cells with scaffolding polymers in an
attempt to generate functional 3-dimensional tissues out-
side of the body that can be tailored in size, shape, and
function according to the respective needs before implan-
tation and improve heart function by integrating cardio-
myocytes into the native organ architecture [6-11].
Generally speaking, there are two main methods for myo-
cardial tissue engineering: one is directly injecting cardio-
myocytes or cardiac-like cells into heart. More recently,
grafting techniques for single cells have been established.
Many researchers have demonstrated that BMMSCs
implantation induces myocardial regeneration and
improves cardiac function through myogenesis and angio-
genesis [12-14]. However, cell implantation studies are
generally hampered by low cell retention and survival as
well as a restricted cardiomyogenic potential in most of
the applied cells [15-18]. Another method is the transplan-
tation of three-dimensional cardiac grafts. Li et al used a
preformed biodegradable gelatin mesh to reconstitute car-
diac myocytes in a three-dimensional structure [19].
Recent advances in cell sheet tissue engineering have
enabled treatment of cardiac failure through the transplan-
tation of cell sheets in animal models [20]. In present
study, we have used a different approach to construct
engineered myocardial tissue using cardiomyocyte-like
cells derived from bone marrow mesenchymal stem cells
and PLGA scaffold. The technique employed PLGA to
support the endogenous capability of induced cells to
form a heart tissue-like structure.
Methods
polyclonal mouse anti-a-actin (sarcomeric, Boster), poly-
clonal goat anti-troponin I (cTnI, Santa Cruz), polyclo-
nal rabbit anti-connexin 43 (anti-Cx43, Boster), anti-
goat FITC-conjugated IgG (Boster), anti-rabbit FITC-
conjugated IgG (Boster), anti-mouse Cy3-conjugated
IgG (Boster), Hoechst33258 (Sigma, USA), dimethyl
sulfoxide (DMSO, Sigma, USA)
Methods
Isolation and culture of BMMSCs
Bone marrow was aspirated from femur and tibial bones
of 4-week-old male Sprague-Dawley (SD) rats
(approximately 100 g) following dislocation. The mar-
row were collected and diluted with 4 mL of Dulbecco’s
modified Eagle’s medium (DMEM, Hyclone, USA),
mixed with an equal volume of 1.073 g/ml Percoll solu-
tion (Sigma, USA), and then centrifuged at 1500 g for
15 min. The enriched cells were collected from the
interphase and then re-suspended in culture medium.
The cells were plated in a 25 cm
2 flasks and grown in
complete DMEM-low glucose medium supplemented
with 10% fetal bovine serum (Gibco, USA), 100 U/mL
penicillin, 100 μg/mL streptomycin,300 mg/l L-gluta-
mine and 10 mmol/L HEPES at 37°C in a humidified
atmosphere of 5% CO2. After 3 days, non-adherent
hematopoietic cells were discarded and the adherent
cells were washed twice with PBS. The culture medium
was replenished every 3 days. When the density of cell
colonies had reached approximately 90% confluence, the
cells were trypsinized (0.25% trypsin) and transferred to
fresh flasks at 1:2 ratio.
Differentiation of cardiomyocyte-like cells
BMMSCs at passage 3 were induced to differentiation
via incubating with complete medium containing 10
mM 5-azacytidine (Sigma, USA) and 0.1 mM angioten-
sin II (Sigma, USA) for 24 h. Afterwards, the cells were
washed 3 times with phosphate buffer solution and the
medium was changed to complete medium without 5-
aza and AngII [21]. The medium was changed every 3
days. The experiment terminated 3 weeks after the drug
treatment, then the cells were prepared for the following
experiments.
Scaffolds preparation
The scaffolds consisted of 50%-polylactic acid (PLA) and
50%-polyglycolic acid (PGA). The molecular mass of
PLA and PGA were 20 kDa. The porous microstructure
was created as described by using a particulate leaching
method with salt grains of 150-200 μm in diameter;
resulting in 90% porosity. The sponges were sliced into
squares (10 mm×10 mm×1 mm). Before cell seeding,
t h es c a f f o l d sw e r es t e r i l i z e db yC o
60 irradiation,
immersed in phosphate buffer saline for 1 h, and then
in DMEM for 1 h. The cardiomyocyte-like cells were
trypsinized for 2 to 3 minutes.2 mL of cell culture med-
i u mw a sa d d e dt os t o pt h edigestion. After being
pipetted, the suspension was collected in a 15-mL tube.
The cell number was determined with a cell counter.
The tube containing the cell suspension was centrifuged
for 5 minutes at 1000g. After the supernatant was
removed, the cell pellet was re-suspended in 1 ml of
culture medium (5~8 × 10
8 cells/ml). The suspension
was slowly placed onto the surface of squares of pre-
soaked PLGA scaffolds which were 10 mm in length, 10
mm in width and 1 mm in height. After another 4 hour,
1 mL of culture medium was carefully added to sub-
merge the graft totally. Grafts were incubated at 37°C,
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scaffold graft were created by the same way. For use as
controls, squares of PLGA scaffolds were placed in cul-
ture medium without any cell inoculation.
Animal Study
Thirty-six Male Sprague-Dawley rats (250-300 g) were
randomly assigned into three groups: the PLGA -Cardi-
omyocyte-like cells group (PC group) received implanta-
tion of cardiomyocyte-like cells -seeded scaffold (n =
12), the PLGA-BMMSCs group received BMMSCs-
seeded scaffold (PB group) (n = 12), and the control
group received a cell-free scaffold (n = 12). All proce-
dures were performed in accordance with protocols
approved by the Fourth Military Medical University
Animal Research Committee and international research
animal care guidelines. Peritoneal implantation of the
cell-scaffold graft was performed 3 days after cell seed-
ing in the PLGA scaffold and cultivation in vitro. The
rats were anesthetized with pentobarbital (3%). Under
sterile conditions, a small incision was made in the
shaved abdominal wall and a pocket was formed. Then,
a cell seeded or empty scaffold was placed inside the
peritoneal pocket of each animal. The abdomen was
closed by muscle and skin sutures and the animal was
monitored until completely recovered from the anesthe-
sia. Four weeks following implantation the grafts were
harvested, fixed using 4% formaldehyde, paraffin-embed
and sectioned for histological analysis.
Immunofluorescence staining of specific proteins of
cardiomyocyte-like cells
To identify whether BMMSCs induced by 5-aza and
AngII were differentiated to cardiomyocytes, immuno-
fluorescence staining of troponin I (cTnI, Santa Cruz),
sarcomeric a-actin (sarcomeric, Boster), and anti-con-
nexin 43 (anti-Cx43, Boster), of cardiomyocytes were
performed. Cells were fixed by 4% formaldehyde,
blocked in 2% bovine serum albumin (BSA), stained by
anti-troponin I (polyclonal IgG anti-goat 1:25); anti-con-
nexin 43 (polyclonal IgG anti-rabbit 1:25); and anti-a-
actin (polyclonal IgG anti-mouse 1:300). Negative con-
trols were also employed in each analysis to delete the
disturbance of the primary or secondary antibody. In
addition, the cells on the stained scratches were coun-
terstained with Hoechst 33258 to visualize their nuclei.
The results were observed and photoed with fluores-
cence microscopy (Olympus BX-51, Japan)
Histological and Immunohistochemical Examination
Four weeks after implantation, recipient animals were
sacrificed by pentobarbital overdose. The grafts were
harvested, rinsed in PBS, fixed in 4% paraformaldehyde
for 24 h, embedded in paraffin, cross-sectioned into 10-
mm slices. Sections were stained with hematoxylin and
eosin (H&E) for cells alignment. For immunohistochem-
ical examination of expression of cardiac troponin I, the
sections were incubated at 4°C overnight with the pri-
mary antibodies directed against troponin-I. The incuba-
tion with secondary antibody was at 37°C for 30 min.
The reaction with the diaminobenzidine (DAB) reagent
was 5-10 min. The sections were mounted for micro-
scopic examination with neutral gum. Cells with brown
granular DAB reaction product in the cytoplasm were
considered positive for the protein.
Scanning electron microscopy
After 7 days of implantation, the grafts were harvested
and fixed in 3% glutaraldehyde. Samples were then
coated with a thin layer of gold for 5 min in a Sputter-
coater JFC-1100. The specimen was viewed using a Japan
S-3400N scanning electron microscope operating at a
typical 5 kV accelerating voltage, 20°C and 10
-5 Torr.
Transmission electron microscopy
4 weeks post implantation, the grafts were harvested,
initially fixed in 3% glutaraldehyde, postfixed in 1%
osmium tetroxide and embedded in epoxy resin. Ultra-
thin sections cut horizontally were prepared and double
stained with uranyl acetate and lead citrate. The cellular
ultrastructure was observed with a JEM-2000EX trans-
mission electron microscope (Japan).
Statistical analysis
Data are presented as mean ± S.D. Data were compared
using standard or repeated measures ANOVA where
appropriate. Pairwise comparisons were performed using
a two-tailed Student’s t-test. Differences were considered
significant for P-values < 0.05.
Results
Cellular morphological alterations of BMMSCs by 5-aza
and AngII treatment
3 days after isolation in primary culture, adhered
BMMSCs presenting circular or short spindle-shaped
cells with one nucleus (Figure 1A). These cells began to
proliferate at about day 7, and gradually grew to form
small colonies (Figure 1B). After being subcultured, the
cells were polygonal or long spindle shaped (Figure 1C).
The morphological differentiation from BMMSCs to
cardiomyocyte-like cells evolved gradually. During expo-
sure to 5-aza and AngII, some adherent cells died,
whereas the surviving cells began to proliferate and dif-
ferentiate. 1 week later, the cells showed multinucleation
and extended their cytoplasmic processes with adjacent
cells. Then, the cells aggregated and gradually increased
in size. Three weeks later, the adherent cells were com-
pletely in contacted with adjoining cells and arranged in
uniform direction (Figure 1D).
Cardiomyocyte-specific protein expression during BMMSC
differentiation
After induction, we evaluated the expression of cardio-
myocyte-specific proteins using immunofluorescence
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( F i g u r e2 A )a n dc o n n e x i n4 3( F i g u r e2 E )p r o t e i n sw e r e
observed in the cells by week 3 of differentiation in 5-
aza and AngII. Red fluorescence-labeled sarcomeric a-
actin was also observed in the induced cells (Figure
2B, F). The cells nuclei were counterstained with
Hoechst 33258 (Sigma, USA) (Figure 2C, G). When
cTnI proteins was merged with sarcomeric a-actin pro-
teins, the majority of the cells showed yellow fluores-
cence, indicating that the cells were double-positive for
both cTnI and sarcomeric a-actin proteins (Figure 2D,
H).
Macroscopic and histological characterization of the
engineered myocardial tissue
Figure 3A showed us the peritoneal pocket. Figure 3B
showed us the cell seeded or empty scaffold which was
placed inside the peritoneal pocket. One day after
implantation, most EMTs still keep the same size and
shape, only a few began to attach to greater momentum
Figure 1 BMMSCs’ morphological alterations after inducement (A) BMMSCs cultured for 3 days (magnification: ×100). (B) BMMSCs
cultured for 7 days (magnification: ×100). (C) BMMSCs of passage 3 (magnification: ×100). (D)Induced BMMSCs showed long spindle-shaped cells
and showed uniform direction 3 weeks after induction. (Magnification: ×200).
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to the greater momentum. Fourteen days later, the size
of EMTs deflated and the shape of EMTs changed
because of slight scaffolds degradation (Figure 3D).
Twenty-eight days later, the EMTs had integrated with
the greater omentum and about 50% scaffolds had
degradated. Standard H&E staining of the implantation
site 28 days after implantation showed that the cells
were spread along the PLGA polymer fibers. Histological
inspection of the engrafted tissue-constructs revealed
the presence of differentiated forms of myocardial tissue.
Moreover, some of the constructs appeared to have
undergone structural maturation, although they still
appeared to be less structurally mature than native car-
diomyocytes. Structural maturation was manifested by
the presence of an elongated pattern, apparent orga-
nized striations, and a low nucleus to cytoplasm ratio
(Figure 3E). Direct differentiation from BMMSCs to the
cardiomyocytes-like cells seemed few (Figure 3F). In the
control group, there was no cardiomyocytes-like cells
(Figure 3G). The presence of erythrocytes proved their
identity as functioning blood vessels.
Immunohistochemical analysis of the the engineered
myocardial tissue
Immunohistochemical examination showed that cells in
these constructs contained many differentiated cardiac
myocytes as assessed by immunohistochemical labeling
of cTnI (Figure 4A), which revealed the presence of car-
diomyocyte-like tissues within the implanted scaffolds in
all animals. In the contrast, the cardiomyocyte-like tis-
sues were less than those of in PB group. As can be
seen from Figure 4B, the constructs only contained less
than 30% differentiated cardiac myocytes. However, the
constructs in control group were not positive for cTnI
(Figure 4C).
Scanning electron micrographs of the engineered
myocardial tissue
Scanning electron microscopy showed that the inocu-
lated cells well attached to PLGA, and the cells grew,
proliferative in 3 dimensions in constructs (Figure 5A).
Many cell enations could be seen in the surface or in
the hole of PLGA, which indicated that the cells had
good adhesion (Figure 5B, C). In addition, the cells
could secrete a lot of extracellular matrix which are
essential for cell differentiation (Figure 5D).
Ultramicrostructural characterization of the engineered
myocardial tissue
Transmission electron micrographs of constructs cul-
tured in vivo demonstrated the presence of myocyte-like
cells in PC group and PB group, but no cardiomyocyte-
like cells were found in control group. The myocyte-like
Figure 2 Immunofluorescence staining for cTnI, connexin 43 and sarcomeric a-actin in induced BMMSCs. The induced cells were positive
for cardiomyocyte-specific proteins cTnI (green fluorescence, panel A, Magnification: × 200), connexin 43 (green fluorescence, panel E,
Magnification: ×400) and sarcomeric a-actin (red fluorescence, panel B, F, Magnification: B: ×200, F: × 400). The nuclei were counterstained with
Hoechst 33258 (blue fluorescence, panel C, G, Magnification:C: ×200, G: × 400). The panels A, B and C were merged as D(Magnification: × 200).
The panels E, F and G were were merged as H(Magnification: × 400).
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was located in the center of the cells (Figure 6A). In PC
group, the constructs were rich in compact mitochon-
dria and endoplasmic reticulum. Uniformly distributed
myofilaments organized with clearly defined z line-like
substances (a distinct electron dense material), which
are the hallmarks of more mature cardiomyocytes, were
also clearly visible (Figure 6B and 6C). In addition, we
could also detect the presence of specialized junctional
structures responsible for electromechanical coupling
between neighboring cardiomyocytes. These included
the presence of intercalated discs containing
Figure 3 Macroscopic and Histological analysis of the implanted tissue-constructs. A: Preparation of the peritoneal pocket. B: EMT in situ
directly after implantation. C: EMT 1 day after implantation. D: EMT 14 days after implantation. E-F: H&E staining of the tissue-constructs after
implantation for 28 days in PC group, PB group and control group respectively (Magnification: × 400).
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PBgroup and control group, respectively (Magnification: × 400).
Figure 5 Scanning electron microscopic images of the EMTs. A: the cells well attached to PLGA (small arrow). B: the cell in the surface of
PLGA (small arrow), and cell enations could be seen (broad arrow). C: the cell in the hole of PLGA (small arrow), and cell enations could be seen
(broad arrow). D: extracellular matrix that the cells secrete (small arrow).
Xing et al. Journal of Biomedical Science 2012, 19:6
http://www.jbiomedsci.com/content/19/1/6
Page 7 of 11desmosomes and gap junctions (Figure 6D and 6E). And
typical capillary composed of several endothelial cells
and a pericyte was observed within the construct (Figure
6F). In PB group, the myocytes-like cells were fewer and
were characterized by the presence of relatively disorga-
nized myofilaments, but no desmosomes and gap junc-
tions were found in this group. In contrast, no
myofilaments, z line-like substances, desmosomes and
gap junctions were detected in control group.
Discussion
Myocardial tissue engineering aims at providing contrac-
tile heart muscle constructs for replacement therapy. At
present, most myocardial tissue engineering attempts to
utilize neonatal heart cells. However, due to limitation
ability of proliferation, the heart cells can not provide
the large number of the cell sources needed for engi-
neered myocardial tissue. Over the past few years several
teams have claimed that adult stem cells such as bone
marrow stem cells can develop into a wide variety of
cell types, including cardiomyocytes. Among them, most
studies have considered bone marrow mesenchymal
s t e mc e l l s( B M M S C s )a sas o u r c eo ft h e“repair stem
cell” [22]. BMMSCs are pluripotent cells and can pro-
duce growth factors and cytokines that play a role in
their proliferation or differentiation abilities [23]. In
addition, BMMSCs have immunomodulatory capabilities
[24,25] as demonstrated in the field of bone marrow
graft-verse-host disease [26]. Under given conditions,
BMMSCs can differentiate into cells exhibiting some
Figure 6 Transmission electron microscopic images of the EMTs.A :R e p r e s e n t a t i v ec a r d i o m y o c y t e - l i k ec e l l( s m a l la r r o w ) .B :U n i f o r m l y
distributed myofilaments (small arrow). C: Z line-like substances, a distinct electron dense material (small arrow). D and E: Presence of the
specialized cell- cell junctions, including the intercalated disc containing desmosomes (small arrow) and gap junctions (small arrow),
characteristic of connections of heart tissue. F: Typical capillary (open arrow) composed of endothelial cells (small arrow) and a pericyte (broad
arrow) is observed within the construct.
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demonstrated that BMMSCs can differentiate into the
cells with cardiac phenotype by treating with 5-azacyti-
dine [31]. Tomita et al reported that the optimal con-
centration for cardiomyogenic differentiation is 10 μM
for 24 h [32]. Others showed that ang II can induce
BMMSCs into the cells with cardiac phenotype. In our
study we combined these two inductors to facilitate car-
diomyogenic differentiation. As a result, the period of
induction decurtate to three weeks compared to that of
induction only using 5-aza. Therefore, on a similar con-
dition of induced culturing, ang II might promote the
differentiation of BMMSCs induced by 5-aza.
The ideal biomaterial should be capable of being safely
replaced by newly formed tissue and it should degrade
at an appropriate time point without producing any
toxic products [33]. PLGA scaffold has some desirable
physical characteristics including high porosity, inter-
connected pore structure, biocompatibility and biode-
gradation, all of which assist in induction of tissue
formation via nutritional diffusion and cell migration. In
addition, PLGA can promote good cellular interaction
a n dd e g r a d e si nas e tt i m ep e r i o dw i t h o u tt o x i c i t y .
While the use of scaffolds can improve initial donor cell
retention and survival following in-vivo engraftment by
preventing cell washout and by supplying the necessary
provisional matrix to which the cells can attach [34].
These scaffold characteristics should increase the survi-
val and growth of the cells. In the present study, cardio-
myocyte-like cells derived from BMMSCs were seeded
on synthetic, 3-dimensional, biodegradable PLGA poly-
mer scaffolds and cultured in vivo.
Vascularization is a prerequisite for successful repair-
ing myocardial infarctions or correcting heart defects. In
our study, histological analysis demonstrated the pre-
sence of red blood cells in many blood-vessels within
the implanted tri-culture scaffolds, suggesting the pre-
sence of functional vasculature. These results were pro-
mising and indicated that EMTs survived after
implantation in vivo, are vascularized and do not dedif-
ferentiate. This is an important requisition for further
experiments with implantations of EMTs on the heart
and for successful clinical trial in the future. But the
present experiments cannot distinct between blood ves-
sels derived from the host and those possibly derived
from EMTs. It is likely that the majority of blood vessels
seen in the constructs were host vessels, but the exis-
tence of vascular structure is likely to facilitate the survi-
val of EMTs in vivo. This factor could be a major
advantage of the myocardial engineering tissue approach
in comparison to cell transplantations.
Imaging by transmission electron microscopy revealed
that EMTs are relatively uniform in terms of ultrastruc-
ture. Among the various morphological features
detected, the presence of myofilaments, z line-like sub-
stances, and desmosomes and gap junctions might help
to explain the capacity of the cells for growth and
migration within EMTs in vivo [35]. Although cell/scaf-
fold implantation can culture relatively mature EMTs,
the contraction of the implanted constructs would
require the electrophysiological integration with host tis-
sue. In this respect it is interesting to note the develop-
ment of gap junctions between the EMTs as well as the
presence of cardiomyocyte-like cells with sarcomeric
structures within the implanted scaffold.
In fact, many researchers doubt that the implanted
BMMSCs are enough to differentiate into the cells with
cardiac phenotype. Taking this doubt into account, we
treated BMMSCs with 5-aza and angII prior to implan-
tation studies. Our results showed that pre-treatment of
BMMSCs ensure that the differentiation process will be
directed towards the cardiomyogenic lineage in vivo
environment and our findings indicate that cardiomyo-
cyte-like cells and PLGA scaffolds in combination have
synergistic effects and are more effective than BMMSCs
and PLGA scaffolds or scaffolds alone.
Except for the implanted cardiomyocyte-like cells,
there are some peritoneal mesothelial cells which help
the growth of engineered myocardial tissues. Mesothelial
cells (MCs) are accessible in human patients by excision
and digestion of epiploon or from peritoneal fluid or
lavage. They are easy to culture to obtain large quanti-
ties in vitro and they can be genetically modified with
interesting therapeutic genes [36-38]. These cells also
display angiogenic properties that could be of interest in
infarct scar remodeling. The important potential of MCs
in tissue engineering has recently been underlined and
this cell type is probably the precursor of coronary
arteries during embryogenesis [39,40]. They have already
been proposed for use in patients to seed vascular pros-
theses [41]. MCs secrete a broad spectrum of angiogenic
cytokines including SDF-1a, growth factors and extracel-
lular matrix [42,43]. MCs are transitional mesodermal-
d e r i v e dc e l l sa n dc o n s i d e r e da sp r o g e n i t o rs t e mc e l l ,
have similar morphological and functional properties
with endothelial cells and conserve properties of trans-
differentiation. MCs therapy in myocardial infarction
induced neoangiogenesis in infarcted scar and preserved
heart function. In conclusion, a potential therapeutic
strategy would be to implant or re-implant genetically
modified MCs in post-infarction injury to enhance tissue
repair and healing. Imparting therapeutic target genes
such as angiogenic genes would also be useful for indu-
cing neovascularization [44]. Therefore, we think that
M C sh a v ea ni m p o r t a n tr o l ei nt i s s u er e p a i r .I ns p i t eo f
these, the function of engineered myocardial tissues is
also important, including the properties of heart beating.
In order to test its function, the ischemic heart model is
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but also need a long period to study, but we believe that
the engineered myocardial tissues have potential of
heart beating and repairing the damaged heart tissue. So
we still need to further our study to investigate these
problems in-depth in the future.
Until now, the mechanism oft h ef o r m a t i o no fE M T s
is still unclear. Many researchers believe that the para-
crine effects of the implanted cells are more likely to
influence the growth and survival of EMTs than any
direct effect of the implanted cells. Nevertheless, the
present results appear to indicate that tissue microenvir-
onment in vivo is thought to play a major role in the
survival and mature of EMTs, and the load in the
pocket is sufficient at least to maintain the myocardial
structure.
Despite these encouraging results, several obstacles
need to be overcome before this strategy can become a
clinical reality. These include the need to generate a
directed and more efficient differentiating system to
promote the differentiation rate of BMMSCs, the need
to scale up the entire process to derive clinically relevant
number of cardiomyocyte-like cells, and the need to
establish stable culture system in vivo to derive more
reliable and more mature engineered myocardial tissue.
As other important issues, inflammation and immune
response have to be considered. While inflammation
caused by the surgical intervention cannot be completely
avoided, an additional inflammatory response or
immune response to scaffold materials or its degrada-
tion products might be existed.
Conclusion
In summary, our study demonstrated that the cardio-
myocyte -like cells derived from BMMSCs cultured on
3-dimensional PLGA scaffolds under implantation in
peritoneal pocket can form engineered myocardial tissue
with structural and functional features resembling those
of native tissue. After 4 weeks of cultivation in vivo,
engineered myocardial constructs expressed cardiac spe-
cific troponin-I. Ultrastructure of constructs indicated a
differentiated cardiac myocyte phenotype including sar-
comeres, desmosomes, and gap junctions. These grafts
survived at least up to one month in vivo in SD rats. All
of these results provide the encouraging evidence for
the general feasibility of engineered myocardial tissue in
vivo and support the idea that engineered myocardial
tissue can be used as a model of native tissue for studies
of tissue development and function and eventually for in
vivo tissue repair. Despite many critical and unresolved
questions, we believe that myocardial tissue engineering
has a promising perspective for the replacement of
malfunctioning myocardium and reconstruction of func-
tional heart.
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